Company profile: NovelStem
1.1 - Company Overview
Company description
- Provider of diagnostic technology and biotech solutions, including NewStem Diagnostic for early detection of anti-cancer drug resistance aiding targeted cancer treatments, NewStem Therapeutics using proprietary HhESCs for drug and gene screenings to identify genes and drugs for genetic and epigenetic disorders, NewStem Cell Growth Media to improve hPSC growth, and Net Force, a publishing franchise on digital crime, espionage, and crypto.
Products and services
- NewStem Cell Growth Media: hPSC-focused technology delivers better cell growth media for hPSCs by identifying pathways regulating PSC growth
- NewStem Diagnostic: personalized diagnostic tool for early detection of anti-cancer drug resistance, aiding in targeted cancer treatments
- NewStem Therapeutics: proprietary HhESCs are utilized for drug and gene screenings to advance understanding of human biology and identify relevant genes and drugs for genetic and epigenetic disorders
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NovelStem
NxThera
HQ: United States
Website
- Description: Provider of medical technologies for endourology conditions, including benign prostatic hyperplasia (BPH). The company's minimally invasive vapor therapy platform is designed to measurably improve urinary flow and patient quality of life; BPH affects more than 32 million men in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NxThera company profile →
Provision Healthcare
HQ: United States
Website
- Description: Provider of cancer care and proton therapy, offering the ProNova SC360 system (360° treatment with superconducting magnets), integrated dual-energy CBCT for IGRT, fast-scanning IMPT, an independent energy selection system for instantaneous room switching, SBRT, and ARC radiation therapy, with a focus on improving patient care, outcomes, research, education, and charitable causes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Provision Healthcare company profile →
ScandiDos
HQ: Sweden
Website
- Description: Provider of a unique measurement system for radiation therapy in cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ScandiDos company profile →
Molecular Insight
HQ: United States
Website
- Description: Provider of biopharmaceutical innovations in molecular medicine, applying molecular-level disease identification and targeting to improve patient healthcare and address significant unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Molecular Insight company profile →
GeminX Pharmaceuticals
HQ: Canada
Website
- Description: Provider of novel, targeted cancer therapeutics, dedicated to the discovery, development and commercialization of treatments based on research on the Bcl-2 cell death regulation pathway, including the discovery of GX15-070 (obatoclax), a novel small molecule.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeminX Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NovelStem
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NovelStem
2.2 - Growth funds investing in similar companies to NovelStem
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NovelStem
4.2 - Public trading comparable groups for NovelStem
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →